Literature DB >> 29729192

Immunohistochemical and genetic characteristics of a colorectal mucin-rich variant of traditional serrated adenoma.

Takafumi Hiromoto1,2, Takashi Murakami1,2, Yoichi Akazawa1,2, Noriko Sasahara2, Tsuyoshi Saito2, Naoto Sakamoto1, Hiroyuki Mitomi3, Akihito Nagahara1, Takashi Yao2.   

Abstract

AIMS: Recently, several morphological variants of traditional serrated adenoma (TSA) of the colorectum have been recognised, and mucin-rich TSA (MR-TSA) and serrated tubulovillous adenoma (S-TVA) were introduced as distinct morphological variants separate from conventional TSA (C-TSA). This aim of this study was to elucidate the immunohistochemical and genetic characteristics of MR-TSAs. METHODS AND
RESULTS: We performed immunostaining for cytokeratins (CKs) (e.g. CK7 and CK20), mucins (e.g. MUC2, MUC5AC, MUC6, and CD10), β-catenin, and MLH1, and direct sequencing of BRAF/KRAS, in 32 MR-TSAs, 35 C-TSAs, and 23 S-TVAs. Immunohistochemically, all studied cases were positive for CK20, whereas few cases were positive for CK7, with no significant differences between the three groups. Regarding mucin-phenotypic expression, all cases were positive for MUC2 but negative for MUC6 and CD10. MUC5AC positivity was found significantly more frequently in MR-TSAs (53%) than in C-TSAs (26%; P = 0.026). Nuclear β-catenin expression in MR-TSAs was significantly less frequent than in S-TVAs (P = 0.002). MLH1 nuclear staining was retained in all cases. Genetically, MR-TSAs (75%) more frequently harboured BRAF mutation than C-TSAs (49%; P = 0.044) or S-TVAs (4%; P < 0.001), whereas only two cases (6%) of MR-TSA harboured a KRAS mutation, a frequency that was significantly lower than that in C-TSAs (26%; P = 0.047) or S-TVAs (57%; P < 0.001).
CONCLUSIONS: MR-TSAs more frequently harboured BRAF mutations than C-TSAs, and had distinct immunohistochemical characteristics. Our findings indicated that MR-TSAs could be important precursors of BRAF-mutated, microsatellite-stable subtypes of colorectal carcinoma.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990zzm321990BRAFzzm321990zzm321990; zzm321990zzm321990KRASzzm321990zzm321990; mucin-rich variant; serrated tubulovillous adenoma; traditional serrated adenoma

Mesh:

Substances:

Year:  2018        PMID: 29729192     DOI: 10.1111/his.13643

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

1.  Serrated adenomas with a BRAF mutation in a young patient with familial adenomatous polyposis.

Authors:  Kentaro Moriichi; Hiroki Tanabe; Yusuke Ono; Yu Kobayashi; Yuki Murakami; Takuya Iwama; Takehito Kunogi; Takahiro Sasaki; Keitaro Takahashi; Katsuyoshi Ando; Nobuhiro Ueno; Shin Kashima; Hidehiro Takei; Yusuke Mizukami; Mikihiro Fujiya; Toshikatsu Okumura
Journal:  Int J Colorectal Dis       Date:  2020-06-05       Impact factor: 2.571

2.  Clinicopathological and molecular correlations in traditional serrated adenoma.

Authors:  Shigeki Sekine; Satoshi Yamashita; Masayoshi Yamada; Taiki Hashimoto; Reiko Ogawa; Hiroshi Yoshida; Hirokazu Taniguchi; Motohiro Kojima; Toshikazu Ushijima; Yutaka Saito
Journal:  J Gastroenterol       Date:  2020-02-12       Impact factor: 7.527

3.  Gastric and small intestinal traditional serrated adenomas: a detailed morphologic and immunohistochemical analysis.

Authors:  Saba Kiremitçi; Cevriye Cansız Ersöz; Berna Savaş; Arzu Ensari
Journal:  Turk J Gastroenterol       Date:  2020-06       Impact factor: 1.852

Review 4.  Traditional serrated adenoma: an overview of pathology and emphasis on molecular pathogenesis.

Authors:  Aoife J McCarthy; Stefano Serra; Runjan Chetty
Journal:  BMJ Open Gastroenterol       Date:  2019-07-24

5.  Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer.

Authors:  Sebastian Dwertmann Rico; Doris Höflmayer; Franziska Büscheck; David Dum; Andreas M Luebke; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Christina Möller-Koop; Daniel Perez; Jakob R Izbicki; Michael Neipp; Hamid Mofid; Hannes Lárusson; Thies Daniels; Christoph Isbert; Stephan Coerper; Daniel Ditterich; Holger Rupprecht; Albert Goetz; Christoph Fraune; Katharina Möller; Anne Menz; Christian Bernreuther; Till S Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Ronald Simon; Stefan Steurer; Patrick Lebok; Eike Burandt; Till Krech; Andreas H Marx
Journal:  Med Mol Morphol       Date:  2020-12-29       Impact factor: 2.309

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.